AMBITION

Do you have type 2 diabetes and are treated with metformin and/or another anti-diabetes medication?

If your answer is **YES** – consider joining AMBITION 3, a research study involving 1200 people from 21 countries across the world.

AMBITION 3 is being done to see how well a new investigational study medicine (zenagamtide) lowers blood sugar and body weight compared to an already approved medicine (semaglutide), in people with type 2 diabetes.

You may qualify to participate in the study if:

- You are 18 years or older
- You have been diagnosed with type 2 diabetes for at least 6 months
- You have been taking metformin and/or an SGLT2 inhibitor (e.g., empagliflozin, dapagliflozin) for at least 3 months
- You are living with obesity (BMI $\geq$ 30 kg/m^2)
- You have a desire to lose weight

Note: *Treatment with any other medicine with a glucagon-like peptide-1 (GLP-1) receptor agonist effect or amylin analogues within the last year is not permitted, as the study medicine has similar effects.*

Participating in a research study

On top of the regular care that you receive from your usual doctors, in this study you will also:

- Receive study-related health checks and medical tests.
- Be able to have conversations about your health with a team of specialised doctors and nurses.
- Have regular monitoring of your overall health.
- Contribute to medical research with information that may help people with type 2 diabetes.

This study is currently recruiting – please contact:

Clinical Trials at Southern New Hampshire Health
Email: FMPClinicalTrials@SNHHS.org
Phone: 603-577-7574

Southern New Hampshire Health

novo nordisk®

AMBITION

Do you have type 2 diabetes and are treated with metformin and/or another anti-diabetes medication?

If your answer is YES – consider joining AMBITION 4, a research study involving 1060 people from 16 countries across the world.

AMBITION 4 is being done to see how well a new investigational medicine (zenagamtide) lowers blood sugar and body weight compared to an already approved medicine (semaglutide), in people with type 2 diabetes.

- **You may qualify to participate in the study if:**
- You are 18 years or older
- You have been diagnosed with type 2 diabetes for at least 6 months
- You have been taking metformin and/or an SGLT2 inhibitor (e.g., empagliflozin, dapagliflozin) for at least 3 months
- You have excess body weight (BMI ≥ 25 kg/m^2)

Note: *Treatment with any other medicine with a glucagon-like peptide-1 (GLP-1) receptor agonist effect or amylin analogues in the past 3 months is not permitted, as the study medicine has similar effects.*

Participating in a research study

On top of the regular care that you receive from your usual doctors, in this study you will also:

- Receive study-related health checks and medical tests.
- Be able to have conversations about your health with a team of specialized doctors and nurses.
- Have regular monitoring of your overall health.
- Contribute to medical research with information that may help people with type 2 diabetes.

This study is currently recruiting – please contact:

Clinical Trials at Southern New Hampshire Health
Email: FMPClinicalTrials@SNHHS.org
Phone: 603-577-7574

Southern New Hampshire Health

novo nordisk®